A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recommended dose for the subsequent studies.

Trial Details

NCT ID
NCT06592638
Phase
PHASE1
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ZG006
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311
  • Plantation, Florida, United States|26.13421,-80.23184
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • Canton, Ohio, United States|40.79895,-81.37845
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Small cell lung cancer (SCLC), who failed or intolerant to available standard treatments;
  • Tissue sample positive for DLL3 expression;
  • Life expectancy ≥ 3 months;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →